Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells.

Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells. bioRxiv : the preprint server for biology Bravo, D. T., Vaidyanathan, S., Baker, J., Sinha, V., Tsai, E., Roozdar, P., Kong, W. W., Atkinson, P. J., Patel, Z. M., Hwang, P. H., Rao, V. K., Negrin, R. S., Wine, J. J., Milla, C., Sellers, Z. M., Desai, T. J., Porteus, M. H., Nayak, J. V. 2025

Abstract

Modulator agents that restore cystic fibrosis transmembrane conductance regulator (CFTR) function have revolutionized outcomes in cystic fibrosis, an incurable multisystem disease. Barriers exist to modulator use, making local CFTR gene and cell therapies attractive, especially in the respiratory tract. We used CRISPR to gene-correct CFTR in upper airway basal stem cells (UABCs) and show durable local engraftment into recipient murine respiratory epithelium. Interestingly, the human cells recapitulate the in vivo organization and differentiation of human sinus epithelium, with little expansion or contraction of the engrafted population over time, while retaining expression of the CFTR transgene. Our results indicate that human airway stem cell transplantation with locoregional restoration of CFTR function is a feasible approach for treating CF and potentially other diseases of the respiratory tract.

View details for DOI 10.1101/2025.01.24.634776

View details for PubMedID 39896581

View details for PubMedCentralID PMC11785248